Clinical Trials on Solid Malignancies in Hong Kong

Total 110 results

AstraZeneca

Completed

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
New Beta Innovation Limited

Terminated

A Safety Study of YQ23 in Advanced Solid Tumors Patients

Advanced Solid Tumor

Hong Kong
Chinese University of Hong Kong

Completed

MOSE to Improve the Diagnostic Accuracy During EUS-guided FNA Using a 19-gauge Needle for Solid Lesions

Solid Tumor

Hong Kong
The University of Hong Kong

Recruiting

oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort

Cancer | Graft Vs Host Disease | Haematological Malignancy

Hong Kong
The University of Hong Kong

Completed

Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia

Childhood Solid Tumor

Hong Kong
The University of Hong Kong

Recruiting

The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies (PIPAC)

Peritoneal Metastases

Hong Kong
ASLAN Pharmaceuticals

Completed

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

Solid Tumor

Taiwan, Hong Kong
New Epsilon Innovation Limited

Active, not recruiting

An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

Advanced Solid Tumor | Relapsed AML | Refractory AML

Hong Kong
Hong Kong Children's Hospital
The University of Hong Kong

Recruiting

Propofol vs Sevo for Paediatric Tumor Surgery

Carcinoma | Cancer | Solid Tumor | Malignancy

Hong Kong
Chinese University of Hong Kong

Completed

Minimally Invasive Evaluation of Dyspepsia by Combined Magnetically Controlled Capsule Endoscopy and Urea Breath Test: a Pilot Prospective Cohort Study (MCUDYSPEPSIA)

Dyspepsia | Gastroesophageal Reflux | Peptic Ulcer Disease | Pancreatobiliary Disease | Ugi Malignancies

Hong Kong
Treadwell Therapeutics, Inc
TIO Discovery Engine

Recruiting

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

United States, Hong Kong, Canada
Amgen

Active, not recruiting

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

Taiwan, Hong Kong
CStone Pharmaceuticals

Completed

A Study of CS1002 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

Hong Kong, Australia
Novartis Pharmaceuticals

Completed

An East Asian Study of LDE225

Medulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor Cancers

Taiwan, Hong Kong, Japan
Harbour BioMed US, Inc.

Completed

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia, China, Hong Kong
Novartis Pharmaceuticals

Terminated

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Solid Tumors

United States, Taiwan, Spain, Canada, Italy, Singapore, Japan, Hong Kong
Boston Pharmaceuticals

Completed

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Advanced Nonhaematologic Malignancies

United States, Korea, Republic of, Taiwan, France, Hong Kong, Belgium, Spain
Novartis Pharmaceuticals

Completed

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Hepatocellular Carcinoma (HCC) | Solid Malignancies

United States, Germany, Taiwan, Spain, Singapore, France, Japan, Korea, Republic of, Hong Kong, China, Italy
ORIC Pharmaceuticals

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Solid Tumors

Korea, Republic of, United States, Australia, Taiwan, Poland, Canada, Hong Kong, United Kingdom
Miller Children's & Women's Hospital Long Beach
Children's Hospital of Orange County

Recruiting

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence (Metronomic)

Solid Tumor

United States
Omega Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I)

Hepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-Resectable

United States, Hong Kong, Korea, Republic of, Singapore, Taiwan
3D Medicines (Beijing) Co., Ltd.

Withdrawn

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

China
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Breast Cancer | Colorectal Cancer | Solid Tumor | Glioblastome Multiforme

United States
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Novartis Pharmaceuticals

Recruiting

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

ALK Positive Malignancies

Germany, France, Australia, Belgium, Italy, Korea, Republic of, Poland, China, United States, Taiwan, Brazil, Bulgaria, Hong Kong, Japan, Lebanon, Malaysia, Spain, Russian Federation, Colombia, Singapore, Czechia
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors

United States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
Pfizer

Active, not recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Ovarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced Malignancies

Hungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Breast Cancer | Advanced Malignant Solid Tumors

United States, Taiwan, United Kingdom, Hong Kong, Belgium, France, Spain, China, Netherlands, Poland, Sweden
Novartis Pharmaceuticals

Completed

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Advanced Solid Tumors

United States, Canada, France, Taiwan, Belgium, Spain, Singapore, Italy, Australia, Hong Kong, Germany, Japan
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Liver Failure | Advanced or Metastatic Solid Tumor

France, United States
Novartis Pharmaceuticals

Recruiting

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Advanced Solid Tumors

Switzerland, Korea, Republic of, Belgium, Canada, Germany, Italy, Spain, United States, Hong Kong, Hungary, China, Czechia, Taiwan, France, Poland, Thailand, Netherlands
Zhujiang Hospital
Guangdong Xiangxue Precision Medical Technology Co., Ltd.; Xiangxue Life Science... and other collaborators

Completed

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Solid Tumor | Breast Cancer Stage IV | Gastric Cancer Stage IV | Ovarian Cancer Stage IV | Liver Cancer Stage IV | Esophageal Cancer, Stage IV | Bone and Soft Tissue Tumors | Bladder Carcinoma Stage IV | Prostate Carcinoma Stage IV | Thyroid Cancer Stage IV

China
Abion Inc

Recruiting

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Advanced Solid Tumors

Korea, Republic of, Taiwan, United States
Gilead Sciences

Active, not recruiting

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (TROPiCS-03)

Metastatic Solid Tumor

United States, Spain, France, Hong Kong, Australia, Belgium, Taiwan, Canada
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

Hematological Malignancy

United States
Hangzhou Zenshine Pharmaceuticals Co., Ltd.

Terminated

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Non-hodgkin Lymphoma

United States
Effector Therapeutics

Completed

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Solid Tumors

United States
Instylla, Inc.

Recruiting

(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds

Arterial Bleeding in Solid Organs and Peripheral Arteries

United States
Novartis Pharmaceuticals

Completed

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Solid Tumors

Germany, United States, Netherlands, Spain, Canada, Hong Kong, Italy, Singapore, Australia, Israel, Korea, Republic of, Taiwan, France, Norway, Thailand
Northwestern University
National Cancer Institute (NCI)

Completed

Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

Fatigue | Unspecified Adult Solid Tumor, Protocol Specific | Cachexia

United States
Amgen

Recruiting

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP)

Advanced MTAP-null Solid Tumors

United States, Canada, Taiwan, Switzerland, United Kingdom, Korea, Republic of, Germany, Austria, France, Belgium, Australia, Hong Kong, Japan
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Registration and Informed Consent Study for the Childhood Cancer Research Network

Unspecified Childhood Solid Tumor, Protocol Specific

United States, Canada
Ningbo Newbay Technology Development Co., Ltd

Recruiting

A Study of NB003 in Patients With Advanced Malignancies

Advanced Solid Tumor

United States, Spain, China, Korea, Republic of, France, United Kingdom
Hoffmann-La Roche

Recruiting

Screening Study for Participants With Malignant Tumors

Solid Tumors

Korea, Republic of, Belgium, Canada, Australia, Brazil, Taiwan, Japan, Singapore, Thailand, Italy, Spain, Turkey, United States, Costa Rica, Hong Kong, Poland, Chile, Serbia, United Kingdom, New Zealand, Colombia, France, Norway
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Glioma | Cholangiocarcinoma | Chondrosarcoma | Any Solid Tumor

United States, Spain, Korea, Republic of, Australia, Japan, Taiwan, France, Singapore, Hong Kong
Pyramid Biosciences

Terminated

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Solid Tumor, Adult | Desmoplastic Small Round Cell Tumor | Brain Tumor, Primary

France, United States, Spain, Hong Kong, United Kingdom, Australia, Singapore, Germany, Korea, Republic of, Italy, Denmark
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
Hoffmann-La Roche

Recruiting

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Solid Tumors

Belgium, United States, Australia, Canada, Japan, Korea, Republic of, United Kingdom, Germany, Taiwan, China, Puerto Rico, Israel, Singapore, Spain, Brazil, Portugal, South Africa, Denmark, Italy, Poland, Hong Kong, France, New Zealand and more

Clinical Trials on Solid Malignancies in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations